CXCL1 and cancer: Although several studies have demonstrated that chemotherapy elicited pro‐metastatic EVs in breast cancer (Keklikoglou et al., 2019; Wills et al., 2021; Yang et al., 2021), to our knowledge, this pioneering study focused on chemotherapy‐induced EVs secreted from apoptotic cancer cells and identified EV‐Apo/CXCL1/TAMs as a novel immune escape axis to fuel chemotherapy‐induced resistance and metastasis.